Chemical name: N-[4-Amino-1-(2-chloroethyl)-2-naphthyl]-5,6,7-trimethoxy-1H-indole-2-carboxamide
Centanamycin, also known as ML-970, AS-I-145 and NSC 716970, is an indolecarboxamide synthesized as a less toxic analog of CC-1065 and duocarmycin, a natural product that binds the A-T-rich DNA minor groove and alkylates DNA.
The compound, an analog of CC-1065 (a DNA minor-groove binding agent) is under preclinical investigation as a novel anticancer agent. Centanamycin has potent in vitro and in vivo cytotoxic activity, with an average GI(50) of 34 nM. Studies have shown that centanamycin is relatively stable in plasma, being largely intact after an 8-h incubation in mouse plasma at 37°C. The compound was extensively bound to plasma proteins.
Centanamycin is only minimally metabolized by the enzymes present in S9 preparation and is not appreciably excreted in the urine or feces. In research studies the solution formulation provided higher C(max), AUC, F values, and greater bioavailability, although the suspension formulation resulted in a later T(max) and a slightly longer T(1/2).